An Interview With Cogstate Neuropsychologist Robert McCue

CNS clinical outcome assessment — particularly performance-based outcome measures — are among the most complex and nuanced assessments in clinical trials. This complexity's potential impact on data quality and signal detection invites the innovative use of technology to streamline test administration and scoring, such as the use of advanced eCOA ecosystems paired with expert clinical scientific guidance to design workflows. This teamwork enables dramatic improvements in assessment data collection. The ultimate goals are more confident decision-making, more conclusive research, and faster delivery of new medicines to the patients who need them.

By now, it should be clear to everyone that hybrid trials are here to stay. Our customers are seeing the benefits, and now others are taking notice.

But what defines these trials? And what are the best practices and best resources to really make them work?

The foundation is eSource – more specifically, direct data capture (DDC), as opposed to EDC. From complicated ClinROs to BYOD, Clinical Ink has pioneered and set the bar for virtual and hybrid trials, and I can tell you that it takes a thoroughly proven, tightly integrated technology toolkit to coordinate all the disparate tasks involved in these trials.

This blog explains what DDC is and how it’s really the only methodology that will afford you the flexibility, speed, site efficiency, and data quality you need to make your trials successful.